JP2020508356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508356A5 JP2020508356A5 JP2019567501A JP2019567501A JP2020508356A5 JP 2020508356 A5 JP2020508356 A5 JP 2020508356A5 JP 2019567501 A JP2019567501 A JP 2019567501A JP 2019567501 A JP2019567501 A JP 2019567501A JP 2020508356 A5 JP2020508356 A5 JP 2020508356A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- alkyl
- aryl
- alkenylene
- alkynylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 81
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- -1 time Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 3
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 206010002022 amyloidosis Diseases 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 2
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000023769 AA amyloidosis Diseases 0.000 claims 1
- 208000023761 AL amyloidosis Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims 1
- 208000021908 Myocardial disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 102100029290 Transthyretin Human genes 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000027121 wild type ATTR amyloidosis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762463421P | 2017-02-24 | 2017-02-24 | |
| US62/463,421 | 2017-02-24 | ||
| PCT/US2018/019347 WO2018156845A1 (en) | 2017-02-24 | 2018-02-23 | Methods for treating neurodegenerative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508356A JP2020508356A (ja) | 2020-03-19 |
| JP2020508356A5 true JP2020508356A5 (enExample) | 2021-03-18 |
| JP7158420B2 JP7158420B2 (ja) | 2022-10-21 |
Family
ID=61563555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567501A Active JP7158420B2 (ja) | 2017-02-24 | 2018-02-23 | 神経変性障害を処置するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11077095B2 (enExample) |
| EP (1) | EP3585373B1 (enExample) |
| JP (1) | JP7158420B2 (enExample) |
| CA (1) | CA3054370A1 (enExample) |
| ES (1) | ES3064246T3 (enExample) |
| MA (1) | MA47595A (enExample) |
| PL (1) | PL3585373T3 (enExample) |
| WO (1) | WO2018156845A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3054370A1 (en) | 2017-02-24 | 2018-08-30 | Alzheon, Inc. | Methods for treating neurodegenerative disorders |
| US20250345298A1 (en) | 2022-04-28 | 2025-11-13 | Alzheon, Inc. | Apoe4 correctors and methods of use |
| CN120641092A (zh) | 2022-12-02 | 2025-09-12 | 阿尔泽恩股份有限公司 | 用于用曲米沙特治疗神经变性病症的方法 |
| WO2024123100A1 (ko) * | 2022-12-09 | 2024-06-13 | 경희대학교 산학협력단 | 신규 아밀로이드-베타 응집체 분해제와 이를 이용한 뇌 표적화 약물 전달 시스템 |
| KR102942879B1 (ko) * | 2022-12-09 | 2026-03-24 | 경희대학교 산학협력단 | 신규 아밀로이드-베타 응집체 분해제와 이를 이용한 뇌 표적화 약물 전달 시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| US5858326A (en) * | 1995-06-06 | 1999-01-12 | Neurochem, Inc. | Methods of increasing amyloid deposition |
| CA2369997C (en) * | 1999-04-28 | 2009-11-17 | Queen's University At Kingston | Compositions and methods for treating amyloidosis |
| WO2003104178A1 (en) | 2002-06-07 | 2003-12-18 | Cortical Pty Ltd | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
| MXPA05013692A (es) | 2003-06-23 | 2006-03-13 | Neurochem Int Ltd | Metodos para tratar trastornos por acumulacion de proteina. |
| US20050137239A1 (en) | 2003-12-17 | 2005-06-23 | Hines Michelle D. | Thiazole derivatives |
| EP1836161B1 (en) | 2004-12-22 | 2016-07-20 | BHI Limited Partnership | Methods and compositions for treating amyloid-related diseases |
| US9522170B2 (en) * | 2011-04-05 | 2016-12-20 | Alphabeta Ab | Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein |
| CA3054370A1 (en) | 2017-02-24 | 2018-08-30 | Alzheon, Inc. | Methods for treating neurodegenerative disorders |
-
2018
- 2018-02-23 CA CA3054370A patent/CA3054370A1/en active Pending
- 2018-02-23 PL PL18708877.8T patent/PL3585373T3/pl unknown
- 2018-02-23 US US16/488,327 patent/US11077095B2/en active Active
- 2018-02-23 JP JP2019567501A patent/JP7158420B2/ja active Active
- 2018-02-23 MA MA047595A patent/MA47595A/fr unknown
- 2018-02-23 ES ES18708877T patent/ES3064246T3/es active Active
- 2018-02-23 EP EP18708877.8A patent/EP3585373B1/en active Active
- 2018-02-23 WO PCT/US2018/019347 patent/WO2018156845A1/en not_active Ceased
-
2021
- 2021-06-25 US US17/358,471 patent/US12036208B2/en active Active
-
2024
- 2024-06-06 US US18/735,806 patent/US20240325354A1/en not_active Abandoned